Recent Quotes

Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company developing cellular therapies designed to reverse, not manage, disease. The company's product candidates include: CLBS119, for the repair of lung damage found in patients with severe COVID-19 infection who experienced respiratory failure, clinical trial to be initiated in 3Q2020 (USA); CLBS12, recipient of a SAKIGAKE (Japan) and ATMP (Europe) designations, eligible for early conditional approval for the treatment of critical limb ischemia based on an ongoing clinical trial (Japan); CLBS16, subject of the completed proof-of-concept ESCaPE-CMD clinical and planned Phase 2B (U.S.A.); and CLBS14, a Phase 3 ready clinical program in no option refractory disabling angina and recipient of a RMAT designation (USA).

Earnings

Q2 2021		Est.		Actual		Surprise
EPS		(EXPECTED)2021-08-05
REV		(EXPECTED)2021-08-05

Q1 2021		Est.		Actual		Surprise
EPS		-0.080		-0.190		-0.1100
REV		660.000K		0		-660.000K

Analyst Ratings

Date	Analyst Firm	Analyst Name	Action	Rating	Action Price	Prior Price	Target

Related Companies

Ticker	Company	Price	Change	Chg %		Mkt Cap
CLBS	Caladrius Biosciences	1.33	-0.02	-1.48%		79.1M

Caladrius Biosciences Frequently Asked Questions

How do I buy Caladrius Biosciences (CLBS) stock?

You can purchase shares of Caladrius Biosciences (NASDAQ: CLBS) through any online brokerage.

View our list of the best stock brokerages.

Who are Caladrius Biosciences's (CLBS) competitors?

Other companies in Caladrius Biosciences’s space includes: Allena Pharmaceuticals (NASDAQ:ALNA), Aziyo Biologics (NASDAQ:AZYO), Eledon Pharmaceuticals (NASDAQ:ELDN), AIkido Pharma (NASDAQ:AIKI) and ImmuCell (NASDAQ:ICCC).

What is the target price for Caladrius Biosciences (CLBS) stock?

The latest price target for Caladrius Biosciences (NASDAQ: CLBS) was reported by Brookline Capital on March 3, 2021. The analyst firm set a price target for 10.00 expecting CLBS to rise to within 12 months (a possible 651.88% upside). 1 analyst firms have reported ratings in the last year.

Current Stock Price for Caladrius Biosciences (CLBS)?

The stock price for Caladrius Biosciences (NASDAQ: CLBS) is $1.33 last updated Fri Jul 30 2021 20:00:03 GMT+0000 (Coordinated Universal Time).

Does Caladrius Biosciences (CLBS) pay a dividend?

There are no upcoming dividends for Caladrius Biosciences.

When is Caladrius Biosciences (NASDAQ:CLBS) reporting earnings?

Caladrius Biosciences’s Q2 earnings are confirmed for after-market on August 5, 2021.

Is Caladrius Biosciences (CLBS) going to split?

There is no upcoming split for Caladrius Biosciences.

What sector and industry does Caladrius Biosciences (CLBS) operate in?

Caladrius Biosciences is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.